NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
It is a naturally occurring substance in humans and organisms. Judging from the fact that breast milk contains NMN, it can be said to be one of the nutrients that humans ingest at the beginning of life. Yellow and green vegetables also contain NMN, so it is different from medicine. NMN is a food of natural origin and is safe.
Recently, a piece of good news came from the Japan Patent Office (one of the largest patent offices in the world) across the ocean to Shenzhen. The patent for "A STABLE NICOTINAMIDE RIBOSE COMPOSITION AND ITS PREPARATION METHOD" applied by Bontac was approved and issued a certificate. This invention patent is of great significance to the stability of Bontac coenzyme series products. This is another new recently patent obtained by Bontac after accumulating more than 150 patent applications. Such impressive achievements in scientific research are undoubtedly the best commendation for the innovative spirit of Bontac Biotech. Invention Title: A STABLE NICOTINAMIDE RIBOSE COMPOSITION AND ITS PREPARATION METHOD Technical advantages: Industrial artificial preparation of nicotinamide ribosehave made considerable progress to prepare relatively pure nicotinamide ribose at a lower cost. However, the monomer will become a viscous solid within a few seconds or minutes under ambient temperature and humidity as nicotinamide ribose is very easy to absorb moisture, and will disintegrate into oil within a few hours. In order to keep nicotinamide ribose as a dry solid, it needs to be stored in an absolutely dry environment, or frozen stored at about -20°C, which severely restricts the commercial application and promotion of nicotinamide ribose. Therefore, the development of stable nicotinamide ribose products has become a major problem that needs to be solved urgently. The purpose of the present invention is to solve the technical problem that the nicotinamide ribose monomer mentioned in the above background art is difficult to preserve and cannot be promoted and applied because it is very easy to absorb moisture and decompose. The invention provides a nicotinamide ribose composition with stable properties, easy storage, transportation and use. Only by continuously innovating technology can we adapt to the new opportunities in the new era, "respond to all changes" before new challenges, and produce a qualitative leap based on quantity. In the current favorable situation, Bontac Biotech's innovation plan is still non-stop, focusing on the overall market direction, paying attention to every link, solving every subtle problem, and writing Bontac's legend with active innovation. At this stage, Bontac Bio will continue to build a better R&D team, increase investment in scientific research, create better products for our customers, and empower greater value.
1. Introduction The gut microbiota has long been regarded as one of the key elements contributing to the regulation of host health. Any changes in the composition or quality of the gut microbiota may have physiological consequences for the host. To determine the effect of sweetener stevia (also known as stevioside) on the gut microbiome of healthy population, the stool samples are collected from healthy participants who consume with or without five drops of the sweetener stevia twice daily. Following analyses of 16S rRNA sequencing method, no large-scale change is found in the gut microbiota post 12 weeks of consumption with stevia, hinting the safety of stevia. 2. Insignificant changes in the alpha or beta diversity following consumption of stevia It is discovered that there is no significant difference in alpha diversity (in terms of observed taxa, evenness and Shannon Index) and beta diversity (with regard to PCoA, PERMANOVA, and Jaccard Index) between groups. Nevertheless, PCoA plots shows strong separation along the x-axis. In addition, the community composition in each group is relatively even over time and equally diverse. 3. No clear difference in relative abundances of taxa At the genus level, relative abundances are similar between the control and stevia groups. No major difference is observed in relative abundances at the class, order and family level. Strikingly, butyricoccus is the only one identified taxon exhibiting significant difference at baseline, but not after 12 weeks of stevia consumption. Moreover, Collinsella and Aldercreutzia are two coprococcus species identified as explicitly different at baseline (one higher and one lower when comparing stevia vs. control), which however are significantly elevated after 12 weeks of consumption with stevia. 4. The safe intake volume of sweetener steviol glycosides In the European Food Safety Authority (EFSA), there is a Panel on Food Additives and Flavourings (FAF), which is responsible for evaluating the safety of food additives and establishing acceptable daily intake levels for safe use. Steviol glycosides, one of the extract from stevia, is evaluated by the FAF as well. In accordance to the latest toxicological test, this sweeter is not genotoxic and carcinogenic, without any adverse effects on the human reproductive system or growing children. The expert group has set the acceptable daily intake (ADI) of steviol glycosides at 4 milligrams per kilogram of body weight per day, which is consistent with the level determined by the Joint Expert Committee on Food Additives (JECFA) administered by the US Food and Agriculture Organization (FAO) and the World Health Organization (WHO). 5. Conclusion Regular, long-term consumption of stevia does not overtly alter the composition of the human gut microbiotia. Stevia can be safe as long as the intake volume is controlled appropriately. Reference Singh G, McBain AJ, McLaughlin JT, Stamataki NS. Consumption of the Non-Nutritive Sweetener Stevia for 12 Weeks Does Not Alter the Composition of the Human Gut Microbiota. Nutrients. 2024;16(2):296. Published 2024 Jan 18. doi:10.3390/nu16020296 BONTAC Stevia/Stevioside (RD) BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team consisting of Doctors and Masters. Patent-grade Stevia Reb-D (US11312948B2 & ZL2018800019752) is availbale at BONTAC. High quality and stable supply of stevioside Reb-D can be better ensured here with the exclusive Bonpure seven-step purification technology and Bonzyme Whole-enzymatic method. Disclaimer This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.
1.Introduction Mitochondria, a type of highly plastic organelle, can maintain a relatively stable dynamic equilibrium state towards the morphology, structure, quantity, volume, quality, and function under normal physiological conditions. This dynamic equilibrium state is generally called mitochondria homeostasis. Replenishment of nicotinamide mononucleotide (NMN) to boost intracellular NAD+ level can regulate mitochondrial homeostasis. 2.The amelioration of mitochondrial dysfunction and senescence post NMN treatment Typically, NAD+ level determines the rate and extent of senescence. The NAD+ pool experienced by cells and tissues presents a declined tendency with age, which may lead to a loss of mitochondrial homeostasis and senescent phenotypes in CD8+ T cells. Following NMN (100 μM) supplementation, NAD+ level is restored and the NAD+/NADH ratio is elevated in senescent CD8+ T cells, by which the mitochondrial functions are obviously improved and the cytoplasmic mtDNA is reduced. 3.The prevention of neuroinflammation and senescence in CD8+ T cells via NMN supplement Post NMN supplementation, the senescence and neuroinflammation are correspondingly repressed. With a great detail, NMN supplementation decreases the ROS and mitochondrial membrane potential in CD8+ T cells, while increasing the intracellular ATP. Furthermore, NMN suppresses the inflammation-associated markers (IL-1β, IL-6, TNF-α and IFN-γ) in the supernatant and the mRNA of senescent CD8+ T cells. 4. The inhibitory effect of NMN on the senescence-related pathway STING The activation of STING can launch a robust proinflammatory response and senescence, which is closely related to the deficient health span in model mice. Strikingly, NMN can prominently improve the senescent state of T cells and reduce the secretion of senescence-related inflammatory factors via inhibition of the STING pathway. 5. Conclusion Upregulation of NAD+ level by NMN supplementation can regulate the mitochondrial homeostasis to prevent STING-induced senescence in CD8+ T cells. Reference Ye B, Pei Y, Wang L, et al. NAD+ supplementation prevents STING-induced senescence in CD8+ T cells by improving mitochondrial homeostasis. J Cell Biochem. 2024;1-17. doi:10.1002/jcb.30522 BONTAC NMN BONTAC is the pioneer of NMN industry and the first manufacturer to launch NMN mass production, with the first whole-enzyme catalysis technology around the world. At present, BONTAC has become the leading enterprise in niche areas of coenzyme products. Notably, BONTAC is the NMN raw material supplier of famous David Sinclair team at the Harvard University, who uses the raw materials of BONTAC in a paper titled “Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of Vascular Aging”. Our services and products have been highly recognized by global partners. Furthermore, BONTAC has the first national and the only provincial independent coenzyme engineering technology research center in Guangdong, China. The coenzyme products of BOMNTAC are widely used in fields such as nutritional health, biomedicine, medical beauty, daily chemicals and green agriculture. Disclaimer This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.